Skip to content

Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease

Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease : Monocentric Study, Controlled, Randomized, Partially Blinded, in Paralleled Groups

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06012097
Acronym
Helping Hand
Enrollment
70
Registered
2023-08-25
Start date
2024-06-04
Completion date
2026-04-01
Last updated
2025-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

De Quervain Disease

Brief summary

De Quervain disease is characterized by an adductor pollicis longus and extensor pollicis brevis tendons inflammation as thys pass beneath the extensor retinaculum at the radial styloid. This pathology is recognized as a musculoskeletal disorder of the upper limb triggering functional deficits resulting to possible modifications in the professional activity, sources of absenteeism, thus constituting an economic cost for society. At the etiological level, this pathology also affects young mothers (it's called mother's wrist or mommy thumb), mobile phone users (textonite, Blackberryte) or video game players (Nintendoite). Currently, the treatment is mainly conservative by splint and anti-inflammatory gel and/or corticosteroid infiltration. Howewer, these therapies have undesirable effects. The interest of this study is therefore to propose another therapy based on aromatherapy gel.

Interventions

using diclofenac as a comparator

DRUGAromatherapy gel

using Aromatherapy gel as an experimetnal treatment

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Male or female patient aged 18 to 75, * Patient with unilateral De Quervain's tenosynovitis, * Patient cared in the Hand Surgery Department, SOS Mains Emergency Department or Rheumatology Department of Strasbourg University Hospitals, * Patient informed of the results of the prior medical examination, * Informed consent signed by the patient, * Patient affiliated to a health insurance social protection scheme or beneficiary, * For a woman of childbearing potential, negative urine pregnancy test at the inclusion visit and maintenance of effective contraception throughout the study.

Exclusion criteria

* Pregnant or breastfeeding patient, * Patient allergic to a component of the gel with essential oils, Dicloflenac®, NSAIDs, or one of the excipients * Patient treated with oral non-steroidal anti-inflammatory drugs * Patient with ongoing treatment with another ointment at the treatment application site (radial edge of the wrist) * Patient with damaged skin, whatever the lesion: oozing dermatosis, eczema, infected lesion, burn or wound, * Patient with atopic skin disease, * Patient with epilepsy or with a history of epilepsy, * Patient with a history of homolateral De Quervain's tenosynovitis, or having already had corticosteroid infiltrations in the 6 months before his inclusion on the ipsilateral side of the pathology, * Patient with associated tendinopathies in the elbow or forearm region, * Impossibility of giving the patient information (patient in an emergency situation, patient with difficulties of understandin, agitation of the patient), * Patient under legal protection, under guardianship or curatorship.

Design outcomes

Primary

MeasureTime frameDescription
Measure of pain during the WHAT testDay 0Visual analogue pain scale (quotation between 0 and 10) during WHAT Test

Countries

France

Contacts

Primary ContactMarie SCHWEBEL
marie.schwebel@chru-strasbourg.fr03 68 76 53 40

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026